【摘要】 目的观察终末期肝病基础上发生肝肾综合征患者的临床特征以及讨论相应治疗方案。方法选取2016年3月至2017年3月来我院就诊的60例终末期肝病基础上发生肝肾综合征患者,对其病症的临床特征进行观察,采取抽签法将60例患者分成数量相同的参照组和观察组,并使用甘露醇联合多巴胺对观察组肝肾综合征患者进行治疗,参照组采用常规治疗方法进行治疗,观察比较两组患者的治疗有效率。结果研究结果显示,观察组肝肾综合征患者使用甘露醇联合多巴胺对其进行治疗后,30例患者治疗总有效率90.0%,高于参照组30例肝肾综合征患者使用常规治疗方法的治疗总有效率80.0%,差异结果经过统计学分析后,P<0.05,差异产生统计学意义。结论使用甘露醇联合多巴胺对终末期肝病基础上发生肝肾综合征患者进行相应治疗,其治疗有效率高于常规治疗方法,因此,甘露醇联合多巴胺对治疗终末期肝病基础上发生肝肾综合征具有临床推广应用价值。更多还原

【Abstract】 Objective To observe the clinical characteristics of hepatorenal syndrome in patients with end-stage liver disease and discuss the corresponding treatment plan. Methods From March 2016 to March 2017,60 patients with hepatorenal syndrome on the basis of end-stage liver disease who visited our hospital were selected.The 60 patients were divided into the reference group and the observation group with the same number by drawing lots. The observation group was treated with mannitol combined with dopamine,while the control group was treated with conventional therapy,and the efficacy of the two groups was compared. Results The total therapeutic response rate of 30 patients in the observation group was 90.0%,which was higher than that of the control group(80.0%),with a significant difference(P <0.05). Conclusion The efficacy of mannitol combined with dopamine in the treatment of hepatorenal syndrome in patients with end-stage liver disease is better than conventional treatment,and mannitol combined with dopamine in the treatment of hepatorenal syndrome in patients with end-stage liver disease has clinical promotion value.更多还原